Successful development continues as demonstrated by the recent launches of new dolutegravir-based products, Tivicay (dolutegravir) and Triumeq
The following ISI is based on the Highlights section of the Prescribing Information for Triumeq.
Discontinue Triumeq as soon as a hypersensitivity reaction is suspected.
Triumeq is ViiV Healthcare s first once-daily single-pill dolutegravir-based regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
Triumeq is a direct result of ViiV Healthcare s patient-centred approach to innovation.
Triumeq is a direct result of ViiV Healthcare's patient-centred approach to innovation.
About Triumeq Triumeq is a once-daily single-pill dolutegravir-based regimen, containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine.
GlaxoSmithKline (NYSE: GSK-Free Report) announced that ViiV Healthcare's Triumeq (a fixed-dose combination of Tivicay, abacavir and lamivudine) has been cleared by the FDA for the treatment of HIV-1 infection.
We are pleased with the approval of Triumeq in the U.
1] Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
Triumeq alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these populations.
About Triumeq Triumeq
(dolutegravir/abacavir/lamivudine) is not currently approved in any country and is an investigational once-daily single tablet dolutegravir based regimen, containing the integrase inhibitor dolutegravir which was approved by the EMA in January 2014 under the brand name Tivicay[sup.